Most recently, Zerhouni was serving as the acting president and CEO of the Diamyd Medical since April 201, though he has been involved in all aspects of the company since 2006.
In his tenure in the company, he has played a vital role in driving forward company’s business and clinical trials.
The company’s pain business area consists of development projects that use the company’s proprietary NTDDS (Nerve Targeting Drug Delivery System) platform to administer drugs directly to the nervous system to treat chronic pain.